Velocity’s North Hollywood research site was founded in 2004 as Providence Clinical Research by Dr. Teresa Sligh and Dr. Scott Sligh, and acquired by Velocity in 2019. The research center focuses on clinical trials for numerous indications, including Type II Diabetes, Anemia, Asthma/COPD, Arthritis of knee and hip, Cardiovascular disease, Chronic low back pain, Constipation, Genital herpes, Gout, Chronic Kidney Disease, Hepatitis B and C, Influenza, Irritable bowel syndrome, Kidney disease, Hypogonadism, Chronic Pain, dermatological disorders, Smoking, and Tinnitus. Our North Hollywood site is an experienced Phase 0 – IV investigative site as well as a special populations contract research organization. Our research facility is specially designed to accommodate all the needs of both inpatient and outpatient studies.
The North Hollywood site has extensive cross-cutting experience spanning all aspects of clinical research. This includes all the phases of preclinical process as well as pharmacoeconomic, pharmacogenomic, and proteomic phases. They have also been involved in pharmaceuticals, biologics, devices, and serologicals/IVD, as well as in both therapeutic and diagnostic indications. Through the thoughtful application of our experience to the conduct of each trial, the North Hollywood staff is able to provide excellence, quality and performance to our clients. Velocity North Hollywood also has a dedicated patient recruitment team with a great track record for enrolling a diverse patient population of approximately 70% people of color.
All trials conducted at the site are performed in accordance with ICH and FDA guidelines, and in compliance with GCP. The North Hollywood team is committed to being a resource for study participants, to providing the highest quality of patient care with compassion and kindness, and to advancing medicine through research.
